While the FAP-targeting agent ensures uptake in the tumor stroma, the cross-fire effect of the radiolabeled (alpha or beta emitting) radionuclides deliver tumoricidal doses to the ECM including the cancer cells. This evidence concerns the gene FAP and neoplasm.